Potential business model for a European vaccine R&D infrastructure and its estimated socio-economic impact.
Jungbluth S, Martin W, Slezak M, Depraetere H, Guzman CA, Ussi A, Morrow D, Van Heuverswyn F, Arnouts S, Carrondo MJT, Olesen O, Ottenhoff THM, Dockrell HM, Ho MM, Dobly A, Christensen D, Segalés J, Laurent F, Lantier F, Stockhofe-Zurwieden N, Morelli F, Langermans JAM, Verreck FAW, Le Grand R, Sloots A, Medaglini D, Lawrenz M, Collin N.
Jungbluth S, et al. Among authors: slezak m.
F1000Res. 2023 Oct 24;12:1401. doi: 10.12688/f1000research.141399.1. eCollection 2023.
F1000Res. 2023.
PMID: 38298529
Free PMC article.